Authors' Reply: Further Considerations on the Clinical Evaluation of Sotagliflozin in Type 1 Diabetes with CKD
J Am Soc Nephrol
.
2025 Dec 1;36(12):2516-2517.
doi: 10.1681/ASN.0000000868.
Epub 2025 Oct 10.
Authors
Vikas S Sridhar
1
,
Ayodele Odutayo
2
,
Michael J Davies
3
,
David Z I Cherney
2
Affiliations
1
Department of Medicine, Division of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada.
2
Department of Medicine, Division of Nephrology, University of Toronto, Toronto, Ontario, Canada.
3
Lexicon Pharmaceuticals, Inc., The Woodlands, Texas.
PMID:
41071616
PMCID:
PMC12677815
(available on
2026-12-01
)
DOI:
10.1681/ASN.0000000868
No abstract available
Keywords:
SGLT2 inhibitors; diabetes mellitus.